Elite Pharmaceuticals, Inc. (OTCMKTS: ELTP) Analyst Report; Action Date Under the Prescription Drug User Fee Act (“PDUFA”
June 13 2016 - 8:00AM
InvestorsHub NewsWire
Northvale, NJ -- June 13th,
2016 -- InvestorsHub NewsWire -- Elite Pharmaceuticals, Inc. (OTCMKTS:
ELTP) a specialty pharmaceutical company that is principally
engaged in the development and manufacture of oral,
controlled-release products, recently announced that it will
present data for SequestOx™ (ELI-200) at the American Pain Society
35th Annual Scientific Meeting being held in Austin, Texas, USA,
May 11 – 14, 2016. The abstract, is entitled Pharmacodynamic
data assessing the abuse potential of a novel abuse deterrent
oxycodone formulation (ELI-200) compared to oxycodone immediate
release, oral intact ELI-200, and placebo in healthy, non-dependent
recreational opioid users following intranasal administration.
SequestOx is Elite’s lead opioid abuse-deterrent candidate and is
an immediate-release Oxycodone Hydrochloride containing sequestered
Naltrexone which incorporates 5 mg, 10 mg, 15 mg, 20 mg and 30 mg
doses of oxycodone into capsules. The New Drug Application
for SequestOX has been accepted and granted priority review by the
United States Food and Drug Administration (“FDA”). The FDA has set
a target action date under the Prescription Drug User Fee Act
(“PDUFA”) of July 14, 2016.
For a more
detailed research report with analyst comments on
Elite Pharmaceuticals, Inc.
(OTCMKTS:
ELTP) please follow the link. There
is no cost obligation required to view analyst brief: http://bit.ly/1UnxVQk-ELTP-ANALYST-REPORT
FORWARD-LOOKING
DISCLAIMER
This press release may contain
certain forward-looking statements and information, as defined
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and is subject
to the Safe Harbor created by those sections. This material
contains statements about expected future events and/or financial
results that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance or achievements of the subject company
in this report to be materially different from the statements made
herein.
COMPLIANCE PROCEDURE
Content is researched, written and
reviewed on a best-effort basis. Information in this release is
fact checked and produced on a best efforts basis by Robert
Borowski. An outsourced research services provider represented by
Robert Borowski, provided Broad Street Alerts this article or
report. However, we are only human and are prone to make mistakes.
If you notice any errors or omissions, please notify us below.
Broad Street Alerts is not entitled to veto, interfere or alter the
articles, documents or report once created and reviewed by the
outsourced research provider represented by Robert Borowski. The
subject Company has not compensated Broad Street Alerts or Robert
Borowski for the creation or dissemination of this report. Broad
Street Alerts is the party responsible for issuing the press
release and for hosting the full analyst report on Broad Street
Alerts website. Robert Borowski is the author of research report.
This information is submitted to increase awareness for the Broad
Street Alerts brand to our subscriber base and the investing
public.
If you wish to have your company
covered in more detail by our team, or wish to learn more about our
services, please contact us at admin@broadstreetalerts.com. For any
urgent concerns or inquiries, please contact us at
admin@broadstreetalerts.com.
NOT FINANCIAL ADVICE
Broad Street Alerts makes no
warranty, expressed or implied, as to the accuracy or completeness
or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to
be construed as personal financial advice. Readers are encouraged
to consult their personal financial advisor before making any
decisions to buy, sell or hold any securities mentioned
herein.
NO WARRANTY OR LIABILITY
ASSUMED
Broad Street Alerts is not
responsible for any error which may be occasioned at the time of
printing of this document or any error, mistake or shortcoming
Broad Street Alerts has compensated Robert Borowski, up to two
hundred fifty dollars for the distribution rights to disseminate
analyst report. No liability is accepted by Broad Street Alerts
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Broad Street Alerts expressly
disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance
placed on the information in this document. Broad Street Alerts
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
CFA® and Chartered Financial
Analyst® are registered trademarks owned by CFA
Institute.
Source: Broad Street
Alerts
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Sep 2023 to Sep 2024